NCT01098435View on ClinicalTrials.gov

ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

May 31, 2011

Study Completion Date

June 30, 2011

Conditions
Binge Eating Disorder
Interventions
DRUG

RDC-0313 (ALKS 33)

Capsules for daily oral administration

DRUG

Placebo

Capsules containing lactose and no active drug for daily oral administration

Trial Locations (6)

13104

Alkermes' Investigational Study Site, Manlius

27612

Alkermes' Investigational Study Site, Raleigh

43623

Alkermes' Investigational Study Site, Toledo

45040

Alkermes' Investigational Study Site, Mason

55454

Alkermes' Investigational Study Site, Minneapolis

85712

Alkermes' Investigational Study Site, Tucson

Sponsors

Lead Sponsor

Alkermes, Inc.
All Listed Sponsors
lead

Alkermes, Inc.

INDUSTRY